Terrance Coyne serves as the Executive Vice President and Chief Financial Officer at Royalty Pharma plc Class A, a leading biopharmaceutical investment company. With a robust background in finance and strategic management, Coyne has been instrumental in steering the financial operations and growth strategies of Royalty Pharma. Prior to joining Royalty Pharma, he held significant roles at major financial institutions, including serving as the Managing Director and Co-Head of the Healthcare Group at Bank of America Merrill Lynch. His extensive experience in the healthcare and finance sectors has equipped him with the expertise to drive Royalty Pharma's mission to accelerate innovation in the biopharmaceutical industry. In his role at Royalty Pharma, Coyne oversees the company's financial strategy, which includes capital allocation, investment decisions, and financial reporting. Under his leadership, Royalty Pharma has successfully expanded its portfolio and strengthened its position in the market. One of his notable achievements includes leading the company through its initial public offering (IPO) in 2020, which was a significant milestone that enhanced Royalty Pharma's visibility and access to capital. Coyne's strategic vision and financial acumen have been pivotal in ensuring the company's sustained growth and ability to fund groundbreaking medical research and development. Coyne's contributions extend beyond his corporate responsibilities. He is actively involved in industry associations and frequently shares his insights on financial strategies within the biopharmaceutical sector. His leadership style emphasizes transparency and collaboration, fostering a culture of innovation and excellence at Royalty Pharma. With his continued guidance, Royalty Pharma is well-positioned to navigate the complexities of the biopharmaceutical market and continue its mission to improve patient outcomes worldwide.